Objective: To evaluate the efficacy and safety of DCV-based DAAs therapy for chronic HCV infected Chinese patients. Methods: An open-label, non-randomized, prospective study was designed. Fifty-two patients with chronic HCV infection were enrolled. Among them, there was one patient after liver transplantation, 2 patients after kidney transplantation, 3 patients with hepatocellular carcinoma, and 4 patients with HBV infection. Thirteen cases with chronic hepatitis C (one compensated cirrhosis) who were negative for resistance-related variants [NS5A RAS (-)] of gene 1b and NS5A were treated with daclatasvir (DCV) + asunaprevir (ASV) for 24 weeks. Twenty-five cases of CHC (six compensated cirrhosis) with GT 1b, 2a, 3a, 3b, 6a were treated with DCV + SOF ± RBV for 24 weeks. 8 cases with decompensated cirrhosis of gene 1b and NS5A RAS(-) were given DCV + SOF + RBV regimen for 12 weeks. Six cases with decompensated cirrhosis, of gene 2a, 1b, 2a, 3a, 3b, were given DCV + SOF + RBV regimen for 24 weeks. HCV RNA, blood routine test, liver and kidney function, and upper abdominal ultrasound/MRI were measured at baseline, 4 weeks of treatment, end of treatment, and 12 weeks of follow-up. The incidence of adverse events and laboratory abnormalities during treatment were recorded. A t-test was used to compare the measurement data between two groups, and analysis of variance was used to compare the measurement data between multiple groups. Results: Sixteen patients (100%) achieved SVR12 after treatment, with 0% recurrence rate. Rapid virological response (RVR) of the four treatment regimens were 76.92%, 54.17%, 87.50%, and 83.33%, respectively, and 32 patients achieved 100% virological response after the completion of treatment. The incidence of adverse events of chronic hepatitis C with cirrhosis and decompensated cirrhosis was 62.5% and 64.29%, respectively. The most common adverse event was fatigue in CHC (25.00%), and elevated indirect bilirubin in decompensated cirrhosis (42.86%). No serious adverse drug events, deaths or adverse reactions occurred. Conclusion DCV-based DAAs regimen is promising option for the treatment of HCV genotypes, compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, and HCV infection after liver/kidney transplantation in china. Above all, it has high SVR12 with good tolerability and safety profile.

Objective To investigate the nursing effects of Thymosin α1 for injection dilution ( Zadaxin dilution) on the patients with oral ulcers caused by oral endotracheal intubation .Methods One hundred patients with oral ulcers caused by oral endotracheal intubation in the ICU of the Second Affiliated Hospital of Wenzhou Medical University from May 2014 to September 2015 were randomly divided into the observation group ( n=50 ) and the control group ( n=50 ) according to random number table .For the oral care , the patients with oral ulcers were treated with Thymosin α1 for injection dilution and compound chlorhexidine gargle in the observation group and the control group respectively .Therapeutic effects and ulcer healing time were observed and compared between the two groups .Results The clinical therapeutic effects in the observation group was significantly better than that in the control group (P<0.05).The healing time in the observation group was significantly shorter than that in the control group (P<0.05).Conclusions Thymosinα1 for injection dilution has a better effects than compound chlorhexidine gargle on the treatment of oral ulcers in the patients with oral endotracheal intubation .Thymosin α1 for injection dilution is worthy of clinical promotion .

OBJECTIVETo investigate the prevalence and risk factors of diabetic nephropathy in Ningbo Yinzhou district.

METHODSNephropathy screening was conducted among patients with type 2 diabetes mellitus (T2DM) registered in Ningbo Yinzhou district. Demographic information, clinical examination information, diabetes complications and behavioral risk factors of enrolled patients were collected. Logistic regression model was used to identify possible risk factors for the occurrence of diabetic nephropathy.

RESULTSAmong 10 604 T2DM patients included in this study, there were 3744 cases of diabetic nephropathy(35.31%). Univariate analysis showed that gender, age, education level, diabetes duration, glycemic control, hypertension, stroke, smoking and waist circumference were associated with diabetic nephropathy (<0.05 or <0.01). Multivariate logistic regression analysis showed that male, elders, long diabetes duration, hypertension and smoking were independent risk factors of diabetic nephropathy (<0.05 or <0.01).

CONCLUSIONSsDiabetic nephropathy is of high prevalence in T2DM patients. Male patients, elders, and those with long diabetes duration, hypertension and smoking habits are more likely to have diabetic nephropathy.

China ; Diabetes Mellitus, Type 2 ; Diabetic Nephropathies ; Humans ; Hypertension ; Logistic Models ; Male ; Prevalence ; Risk Factors ; Surveys and Questionnaires